Cardeas Pharma Obtains $3,500,000 Series B Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4d2c8c8f-b683-467e-81d9-509ab50392c0
Date
4/10/2015
Company Name
Cardeas Pharma
Mailing Address
2025 First Avenue Seattle, WA 98121 USA
Company Description
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae.
Website
http://www.cardeaspharma.com
Transaction Type
Venture Equity
Transaction Amount
$3,500,000
Transaction Round
Series B
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
M&A Terms
Venture Investor